Your browser doesn't support javascript.
loading
Defining the phenotypic spectrum of SLC6A1 mutations.
Johannesen, Katrine M; Gardella, Elena; Linnankivi, Tarja; Courage, Carolina; de Saint Martin, Anne; Lehesjoki, Anna-Elina; Mignot, Cyril; Afenjar, Alexandra; Lesca, Gaetan; Abi-Warde, Marie-Thérèse; Chelly, Jamel; Piton, Amélie; Merritt, J Lawrence; Rodan, Lance H; Tan, Wen-Hann; Bird, Lynne M; Nespeca, Mark; Gleeson, Joseph G; Yoo, Yongjin; Choi, Murim; Chae, Jong-Hee; Czapansky-Beilman, Desiree; Reichert, Sara Chadwick; Pendziwiat, Manuela; Verhoeven, Judith S; Schelhaas, Helenius J; Devinsky, Orrin; Christensen, Jakob; Specchio, Nicola; Trivisano, Marina; Weber, Yvonne G; Nava, Caroline; Keren, Boris; Doummar, Diane; Schaefer, Elise; Hopkins, Sarah; Dubbs, Holly; Shaw, Jessica E; Pisani, Laura; Myers, Candace T; Tang, Sha; Tang, Shan; Pal, Deb K; Millichap, John J; Carvill, Gemma L; Helbig, Kathrine L; Mecarelli, Oriano; Striano, Pasquale; Helbig, Ingo; Rubboli, Guido.
Afiliação
  • Johannesen KM; The Danish Epilepsy Center Filadelfia, Dianalund, Denmark.
  • Gardella E; Institute for Regional Health Services Research, University of Southern Denmark, Odense, Denmark.
  • Linnankivi T; The Danish Epilepsy Center Filadelfia, Dianalund, Denmark.
  • Courage C; Institute for Regional Health Services Research, University of Southern Denmark, Odense, Denmark.
  • de Saint Martin A; Department of Child Neurology, Children's Hospital, Helsinki University Hospital Helsinki, University of Helsinki, Helsinki, Finland.
  • Lehesjoki AE; The Folkhälsan Institute of Genetics, University of Helsinki, Helsinki, Finland.
  • Mignot C; Research Programs Unit, Molecular Neurology and Neuroscience Center, Helsinki, Finland.
  • Afenjar A; Department of Pediatrics, Pediatric Neurology, University Hospital of Strasbourg, Strasbourg, France.
  • Lesca G; Reference Center for Rare Epilepsies, Strasbourg, France.
  • Abi-Warde MT; The Folkhälsan Institute of Genetics, University of Helsinki, Helsinki, Finland.
  • Chelly J; Research Programs Unit, Molecular Neurology and Neuroscience Center, Helsinki, Finland.
  • Piton A; Department of Genetics, Center for Rare causes of Intellectual Disabilities and UPMC Research Group "Intellectual Disabilities and Autism", Paris, France.
  • Merritt JL; APHP, Genetic Services, Hospital Trousseau, Paris, France.
  • Rodan LH; Departments of Genetics, Lyon University Hospitals, Lyon, France.
  • Tan WH; Claude Bernard Lyon I University, Lyon, France.
  • Bird LM; Lyon Neuroscience Research Center, CNRS UMRS5292, INSERM U1028, Lyon, France.
  • Nespeca M; Department of Pediatrics, Pediatric Neurology, University Hospital of Strasbourg, Strasbourg, France.
  • Gleeson JG; Reference Center for Rare Epilepsies, Strasbourg, France.
  • Yoo Y; Department of Translational Medicine and Neurogenetics, Institut Génétique Biologie Moléculaire Cellulaire (IGBMC), Illkirch, France.
  • Choi M; Laboratory of Genetic Diagnosis, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Chae JH; Department of Translational Medicine and Neurogenetics, Institut Génétique Biologie Moléculaire Cellulaire (IGBMC), Illkirch, France.
  • Czapansky-Beilman D; Laboratory of Genetic Diagnosis, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Reichert SC; Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA.
  • Pendziwiat M; Boston Children's Hospital, Boston, MA, USA.
  • Verhoeven JS; Harvard Medical School, Boston, MA, USA.
  • Schelhaas HJ; Boston Children's Hospital, Boston, MA, USA.
  • Devinsky O; Harvard Medical School, Boston, MA, USA.
  • Christensen J; Division of Genetics, Department of Pediatrics, Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA, USA.
  • Specchio N; Division of Neurology, Rady Children's Hospital, University of California, San Diego, CA, USA.
  • Trivisano M; Rady Children's Institute for Genomic Medicine, Howard Hughes Medical Institute, University of California, San Diego, CA, USA.
  • Weber YG; Department of Biomedical Sciences, Seoul National University School of Medicine, Seoul, South Korea.
  • Nava C; Department of Biomedical Sciences, Seoul National University School of Medicine, Seoul, South Korea.
  • Keren B; Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University School of Medicine, Seoul, South Korea.
  • Doummar D; Pediatric Neurology, Gillette Children's Specialty Healthcare, Burnsville, MN, USA.
  • Schaefer E; Children's Minnesota, Minneapolis, MN, USA.
  • Hopkins S; Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Dubbs H; Department of Neurology, Academic Center for Epileptology, Heeze, The Netherlands.
  • Shaw JE; Department of Neurology, Academic Center for Epileptology, Heeze, The Netherlands.
  • Pisani L; NYU Epilepsy Center, New York, NY, USA.
  • Myers CT; Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
  • Tang S; Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Tang S; Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pal DK; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tüebingen, Tüebingen, Germany.
  • Millichap JJ; Department of Genetics, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Carvill GL; Sorbonne Universities, UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, France.
  • Helbig KL; Department of Genetics, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Mecarelli O; Sorbonne Universities, UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, France.
  • Striano P; Assistance Publique-Hôpitaux de Paris, Neuropediatric Services, Hospital Armand Trousseau, Paris, France.
  • Helbig I; Medical Genetics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Rubboli G; Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Epilepsia ; 59(2): 389-402, 2018 02.
Article em En | MEDLINE | ID: mdl-29315614
ABSTRACT

OBJECTIVE:

Pathogenic SLC6A1 variants were recently described in patients with myoclonic atonic epilepsy (MAE) and intellectual disability (ID). We set out to define the phenotypic spectrum in a larger cohort of SCL6A1-mutated patients.

METHODS:

We collected 24 SLC6A1 probands and 6 affected family members. Four previously published cases were included for further electroclinical description. In total, we reviewed the electroclinical data of 34 subjects.

RESULTS:

Cognitive development was impaired in 33/34 (97%) subjects; 28/34 had mild to moderate ID, with language impairment being the most common feature. Epilepsy was diagnosed in 31/34 cases with mean onset at 3.7 years. Cognitive assessment before epilepsy onset was available in 24/31 subjects and was normal in 25% (6/24), and consistent with mild ID in 46% (11/24) or moderate ID in 17% (4/24). Two patients had speech delay only, and 1 had severe ID. After epilepsy onset, cognition deteriorated in 46% (11/24) of cases. The most common seizure types were absence, myoclonic, and atonic seizures. Sixteen cases fulfilled the diagnostic criteria for MAE. Seven further patients had different forms of generalized epilepsy and 2 had focal epilepsy. Twenty of 31 patients became seizure-free, with valproic acid being the most effective drug. There was no clear-cut correlation between seizure control and cognitive outcome. Electroencephalography (EEG) findings were available in 27/31 patients showing irregular bursts of diffuse 2.5-3.5 Hz spikes/polyspikes-and-slow waves in 25/31. Two patients developed an EEG pattern resembling electrical status epilepticus during sleep. Ataxia was observed in 7/34 cases. We describe 7 truncating and 18 missense variants, including 4 recurrent variants (Gly232Val, Ala288Val, Val342Met, and Gly362Arg).

SIGNIFICANCE:

Most patients carrying pathogenic SLC6A1 variants have an MAE phenotype with language delay and mild/moderate ID before epilepsy onset. However, ID alone or associated with focal epilepsy can also be observed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsias Mioclônicas / Proteínas da Membrana Plasmática de Transporte de GABA / Transtornos do Desenvolvimento da Linguagem / Deficiência Intelectual Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsias Mioclônicas / Proteínas da Membrana Plasmática de Transporte de GABA / Transtornos do Desenvolvimento da Linguagem / Deficiência Intelectual Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article